$CRDF
Cardiff Oncology, Inc. Stock $crdf

$crdf Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000162828018010424 Filed on August 03, 2018

Income Statement

Concept	2018 Q2	2017 Q2
Revenue	$111.8K	$102.0K
YoY Change	9.61%	-1.91%
Cost Of Revenue	$204.4K	$338.2K
YoY Change	-39.55%	-17.4%
Gross Profit	-$92.62K	-$236.2K
YoY Change	-60.78%	-22.68%
Gross Profit Margin	-82.84%	-231.54%
Selling, General & Admin	$2.151M	$4.674M
YoY Change	-53.98%	-16.5%
% of Gross Profit
Research & Development	$1.953M	$981.7K
YoY Change	98.91%	-75.92%
% of Gross Profit
Depreciation & Amortization	$230.0K	$320.0K
YoY Change	-28.13%	-3.03%
% of Gross Profit
Operating Expenses	$4.551M	$5.990M
YoY Change	-24.02%	-40.6%
Operating Profit	-$4.440M	-$5.888M
YoY Change	-24.6%	-41.0%
Interest Expense	$925.00	-$500.0K
YoY Change	-100.19%	127.27%
% of Operating Profit
Other Income/Expense, Net	-$71.84K	$1.566K
YoY Change	-4687.42%
Pretax Income	-$3.750M	-$8.050M
YoY Change	-53.42%	-21.08%
Income Tax
% Of Pretax Income
Net Earnings	-$3.747M	-$8.046M
YoY Change	-53.43%	-21.14%
Net Earnings / Revenue	-3351.09%	-7887.2%
Basic Earnings Per Share	-$5.27	-$3.12
Diluted Earnings Per Share	-$5.27	-$3.12
COMMON SHARES
Basic Shares Outstanding	1.237M shares	2.583M shares
Diluted Shares Outstanding	1.237M shares	2.583M shares

Balance Sheet

Concept	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.50M	$7.800M
YoY Change	137.18%	-84.58%
Cash & Equivalents	$18.49M	$7.784M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$1.000M	$700.0K
YoY Change	42.86%	-22.22%
Inventory
Prepaid Expenses
Receivables	$124.1K	$157.4K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$19.64M	$8.655M
YoY Change	126.95%	-83.23%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.804M	$3.322M
YoY Change	-45.69%	-29.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$320.7K	$584.0K
YoY Change	-45.07%	57.3%
Total Long-Term Assets	$2.125M	$3.906M
YoY Change	-45.6%	-23.47%
TOTAL ASSETS
Total Short-Term Assets	$19.64M	$8.655M
Total Long-Term Assets	$2.125M	$3.906M
Total Assets	$21.77M	$12.56M
YoY Change	73.3%	-77.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$565.4K	$602.7K
YoY Change	-6.19%	-45.96%
Accrued Expenses	$2.303M	$4.930M
YoY Change	-53.28%	35.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$1.600M
YoY Change	-100.0%	-73.77%
Total Short-Term Liabilities	$3.218M	$7.462M
YoY Change	-56.87%	-31.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$1.100M	$1.600M
YoY Change	-31.25%	5.32%
Total Long-Term Liabilities	$1.100M	$1.600M
YoY Change	-31.25%	5.32%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.218M	$7.462M
Total Long-Term Liabilities	$1.100M	$1.600M
Total Liabilities	$4.291M	$9.050M
YoY Change	-52.59%	-62.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$184.3M	-$166.2M
YoY Change	10.88%	28.45%
Common Stock	$7.173K	$3.108K
YoY Change	130.79%	3.08%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$17.48M	$3.511M
YoY Change
Total Liabilities & Shareholders Equity	$21.77M	$12.56M
YoY Change	73.3%	-77.86%

Cashflow Statement

Concept	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$3.747M	-$8.046M
YoY Change	-53.43%	-21.14%
Depreciation, Depletion And Amortization	$230.0K	$320.0K
YoY Change	-28.13%	-3.03%
Cash From Operating Activities	-$3.250M	-$4.600M
YoY Change	-29.35%	-43.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K
YoY Change	-100.0%	-96.88%
Acquisitions
YoY Change
Other Investing Activities	-$30.00K	$18.86M
YoY Change	-100.16%	-167.48%
Cash From Investing Activities	-$30.00K	$18.86M
YoY Change	-100.16%	-166.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	15.11M	-16.66M
YoY Change	-190.7%	1471.7%
NET CHANGE
Cash From Operating Activities	-3.250M	-4.600M
Cash From Investing Activities	-30.00K	18.86M
Cash From Financing Activities	15.11M	-16.66M
Net Change In Cash	11.83M	-2.400M
YoY Change	-592.92%	-93.58%
FREE CASH FLOW
Cash From Operating Activities	-$3.250M	-$4.600M
Capital Expenditures	$0.00	-$10.00K
Free Cash Flow	-$3.250M	-$4.590M
YoY Change	-29.19%	-40.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	trov	Class Of Warrant Or Right Number Granted ClassOfWarrantOrRightNumberGranted	20700000	shares
CY2017	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P4Y4M21D
	trov	Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights	P4Y10M13D
CY2017Q4	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	11.34
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001213037
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17688773	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Entity Registrant Name EntityRegistrantName	Trovagene, Inc.
CY2017Q2	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
CY2018Q2	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Adjustment For Change In Unrealized Gain Loss On Derivatives AdjustmentForChangeInUnrealizedGainLossOnDerivatives	0	USD
	trov	Amortized Portion Of Final Fee Upon Repayment AmortizedPortionOfFinalFeeUponRepayment	293614	USD
	trov	Amortized Portion Of Final Fee Upon Repayment AmortizedPortionOfFinalFeeUponRepayment	0	USD
	trov	Class Of Warrant Or Right Number Exercised ClassOfWarrantOrRightNumberExercised	447108	shares
CY2018Q2	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights	1.94
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised	3.60
	trov	Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted	1.10
CY2017Q2	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-8051895	USD
	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-18060345	USD
CY2018Q2	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-6522548	USD
	trov	Comprehensive Income Loss Availableto Common Stockholders Basic ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic	-11314785	USD
CY2017Q2	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	0	USD
	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	0	USD
CY2018Q2	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	2769533	USD
	trov	Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock	2769533	USD
CY2017Q2	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	55501	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	84363	USD
CY2018Q2	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	39345	USD
	trov	Diagnostic Service Revenue DiagnosticServiceRevenue	79347	USD
	trov	Operating Lease Monthly Rent OperatingLeaseMonthlyRent	68000	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	12120	USD
	trov	Preferred Stock Dividend Accrued PreferredStockDividendAccrued	12120	USD
	trov	Sale Of Stock Value Common And Warrants Net SaleOfStockValueCommonAndWarrantsNet	-11779525	USD
	trov	Stock Issued During Period Value Warrants Exercised Net StockIssuedDuringPeriodValueWarrantsExercisedNet	1612667	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	825244	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	565413	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	77095	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	124082	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-9230	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1454587	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2303366	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2071492	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2175689	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	179546954	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	201720972	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1627431	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	775385	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1696184	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	221300	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1627431	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	113780	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	786122	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28398193	shares
CY2018Q2	us-gaap	Area Of Land AreaOfLand	26100	sqft
CY2017Q4	us-gaap	Assets Assets	12284941	USD
CY2018Q2	us-gaap	Assets Assets	21768042	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	9468687	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	19643372	USD
	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	-6400	USD
	us-gaap	Availableforsale Securities Gross Realized Gain Loss Excluding Other Than Temporary Impairments AvailableforsaleSecuritiesGrossRealizedGainLossExcludingOtherThanTemporaryImpairments	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	13915094	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7783891	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8225764	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18485950	USD
CY2017Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1936641	shares
CY2018Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	22189533	shares
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	4399299	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17305004	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	4399299	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17305004	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	5279	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	7173	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8045835	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18048225	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3746955	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8533132	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	0	USD
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	321	USD
CY2017Q2	us-gaap	Cost Of Revenue CostOfRevenue	338203	USD
	us-gaap	Cost Of Revenue CostOfRevenue	954629	USD
CY2018Q2	us-gaap	Cost Of Revenue CostOfRevenue	204436	USD
	us-gaap	Cost Of Revenue CostOfRevenue	570780	USD
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	334424	USD
CY2018Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	349565	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1183677	USD
CY2018Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1004689	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	645962	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	483495	USD
CY2017Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	649387	USD
CY2018Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	67847	USD
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	56000	USD
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	12120	USD
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.12
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.00
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.88
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.00
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.88
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.88
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	2411	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-28097	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-198099	USD
CY2017Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1655825	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-1655825	USD
CY2018Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	17974	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	17974	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	800	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	280520	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	638701	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	56985	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-62935	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	90330	USD
	us-gaap	Increase Decrease In Accrued Investment Income Receivable IncreaseDecreaseInAccruedInvestmentIncomeReceivable	0	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	136776	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	163847	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	199743	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-243571	USD
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-191321	USD
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2018Q2	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-431871	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-861268	USD
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	35277	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	32812	USD
CY2018Q2	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	0	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-6131203	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	10260186	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-16819328	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16403540	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	24041048	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-36600	USD
	us-gaap	Interest Paid InterestPaid	629952	USD
	us-gaap	Interest Paid InterestPaid	22482	USD
CY2017Q4	us-gaap	Liabilities Liabilities	5778834	USD
CY2018Q2	us-gaap	Liabilities Liabilities	4290880	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12284941	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	21768042	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3945770	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	3218344	USD
CY2017Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	1331515	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-13355334	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-6106754	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-8045811	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18045348	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-3746955	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8533132	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8051871	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-18057468	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6522548	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11314785	USD
CY2017Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-8051871	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-18057468	USD
CY2018Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-6522548	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11314785	USD
	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	109922	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	5990264	USD
	us-gaap	Operating Expenses OperatingExpenses	16210948	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	4551409	USD
	us-gaap	Operating Expenses OperatingExpenses	9306568	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-5888253	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16013899	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4439596	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9094619	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	389942	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	320749	USD
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-9543	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-11942	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	0	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-24	USD
CY2017Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	1700	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	2050	USD
CY2018Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	20045	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	31124	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	1613067	USD
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	175381	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	8804604	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-2877	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9519	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	9065	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1566	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1566	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-71839	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-70839	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	31500	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20738	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5100	USD
CY2017Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12120	USD
CY2018Q2	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	6060	USD
	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	12120	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	60	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	66	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1165828	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1001840	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	106791	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	11779525	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	4386762	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	16431837	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	16434553	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1612667	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4497804	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3979610	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2426312	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1803921	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	15000000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	313052	USD
	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	1200033	USD
CY2017Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	981715	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	5261545	USD
CY2018Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1952767	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3836605	USD
CY2017Q2	us-gaap	Restructuring Charges RestructuringCharges	-3806	USD
	us-gaap	Restructuring Charges RestructuringCharges	1700000	USD
	us-gaap	Restructuring Charges RestructuringCharges	1715998	USD
CY2018Q2	us-gaap	Restructuring Charges RestructuringCharges	243335	USD
	us-gaap	Restructuring Charges RestructuringCharges	243335	USD
	us-gaap	Restructuring Charges RestructuringCharges	243000	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	485000	USD
	us-gaap	Restructuring Costs And Asset Impairment Charges RestructuringCostsAndAssetImpairmentCharges	187500	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-173046186	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-184251049	USD
CY2017Q2	us-gaap	Royalty Revenue RoyaltyRevenue	44810	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	110636	USD
CY2018Q2	us-gaap	Royalty Revenue RoyaltyRevenue	52423	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	101478	USD
CY2017Q2	us-gaap	Sales Revenue Net SalesRevenueNet	102011	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	197049	USD
CY2018Q2	us-gaap	Sales Revenue Net SalesRevenueNet	111813	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	211949	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4674152	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8278776	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2150871	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4655848	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1696184	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1627431	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	2796924	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1246260	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	31500	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4386762	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	6506107	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	17477162	USD
CY2017Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-71428	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	484078	USD
CY2018Q2	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	711229	USD
	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	581540	USD
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2582645	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2581372	shares
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	7423463	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6026345	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2582645	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2581372	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	7423463	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6026345	shares

Files In Submission

Name	View Source	Status
0001628280-18-010424-index-headers.html	Edgar Link	pending
0001628280-18-010424-index.html	Edgar Link	pending
0001628280-18-010424.txt	Edgar Link	pending
0001628280-18-010424-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
trov-063018exhibit311.htm	Edgar Link	pending
trov-063018exhibit321.htm	Edgar Link	pending
trov-063018x10q.htm	Edgar Link	pending
trov-0630x18exhibit41.htm	Edgar Link	pending
trov-20180630.xml	Edgar Link	completed
trov-20180630.xsd	Edgar Link	pending
trov-20180630_cal.xml	Edgar Link	unprocessable
trov-20180630_def.xml	Edgar Link	unprocessable
trov-20180630_lab.xml	Edgar Link	unprocessable
trov-20180630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRDF
Cardiff Oncology, Inc. Stock $crdf

2018 Q2 Form 10-Q Financial Statement

#000162828018010424 Filed on August 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF Cardiff Oncology, Inc. Stock $crdf

2018 Q2 Form 10-Q Financial Statement

#000162828018010424 Filed on August 03, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRDF
Cardiff Oncology, Inc. Stock $crdf